Daunoxome
Brand names,
Daunoxome
Analogs
Daunoxome
Brand Names Mixture
Daunoxome
Chemical_Formula
C27H29NO10
Daunoxome
RX_link
http://www.rxlist.com/cgi/generic2/daunorubicin.htm
Daunoxome
fda sheet
Daunoxome
msds (material safety sheet)
Daunoxome
Synthesis Reference
J. P. Parsh et al. J. Pharm. Sci. 56, 1691 (1967);
Daunoxome
Molecular Weight
527.52 g/mol
Daunoxome
Melting Point
208-209 oC
Daunoxome
H2O Solubility
39.2 mg/L
Daunoxome
State
Solid
Daunoxome
LogP
0.766
Daunoxome
Dosage Forms
Powder for solution; Suspension
Daunoxome
Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunoxome
Pharmacology
Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Daunoxome
Absorption
No information avaliable
Daunoxome
side effects and Toxicity
LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
Daunoxome
Patient Information
Daunoxome
Organisms Affected
Humans and other mammals